• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPharmaceutical Industry

Pharmaceutical Industry

Page 89 of 100
Hedge fund manager Bill Ackman
Finance
Another one of Bill Ackman’s top stocks is down 50%
By Jen WiecznerOctober 29, 2015
A Starbucks cafe in Sanlitun. For the third quarter of 2015
Features
Pharma megadeal and Starbucks earnings — 5 things to know today
By Tom Huddleston Jr. and Geoffrey SmithOctober 29, 2015
Allergan Inc.'s Botox Cosmetic As Actavis Plc Buys Drugmaker For $66 Billion
Health
When Viagra met Botox: Pfizer, Allergan eye mega-merger
By Geoffrey SmithOctober 29, 2015
Cholesterol lowering pill
Health
This drug will make your flu shot less effective
By TIMEOctober 29, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance
Valeant accounting scandal: 4 critical questions that have been left unanswered
By Stephen GandelOctober 26, 2015
Why the drug price scandal won’t be enough to keep down prices
Retail
Why the drug price scandal won’t be enough to keep down prices
By Laura LorenzettiOctober 26, 2015
Imprimis Turing Drug
Health
This company is offering a $1 alternative to Turing’s $750 drug
By Laura LorenzettiOctober 23, 2015
MSMB Capital Management CIO Martin Shkreli
Health
This super-expensive drug is getting a $1 rival
By Benjamin SnyderOctober 23, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance
Valeant short seller on pharmacy alliance: It’s the ‘turd in the punch bowl’
By Stephen GandelOctober 22, 2015
J. Michael Pearson, Chairman of the board and Chief Executive Officer of Valeant Pharmaceuticals International Inc., waits for the start of their annual general meeting in Laval, Quebec
Finance
Valeant’s accounting problems: It gets worse
By Stephen GandelOctober 22, 2015
Big pharma won’t stay silent in drug pricing debate for long
Health
Big pharma won’t stay silent in drug pricing debate for long
By Erika FryOctober 22, 2015
New Reasearch Shows That Aspirin May Cut Breast Cancer Risk
Health
The world’s biggest clinical trial is for one of the cheapest drugs
By Claire GrodenOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance
Forget the plunging stock price, here’s Valeant’s biggest problem
By Laura LorenzettiOctober 22, 2015
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Health
Short-seller: Is Valeant the pharmaceutical Enron?
By Laura LorenzettiOctober 21, 2015
519891667
Health
Drug companies are paying huge sums to fast-track FDA approval
By Laura LorenzettiOctober 20, 2015
1...
  • 87
  • 88
  • 89
  • 90
  • 91
...100
Most Popular
Big Tech
As Big Tech showers employees with perks to win the talent war, Nvidia built a nearly $5 trillion company by making people pay for their own lunchplaceholder alt text
By Marco Quiroz-GutierrezJuly 1, 2026
Success
MacKenzie Scott alone accounted for one-third of America's $19.2 billion in megagifts last yearplaceholder alt text
By Sydney LakeJune 25, 2026
Personal Finance
Current price of oil as of July 1, 2026placeholder alt text
By Joseph HostetlerJuly 1, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • World's Most Admired Companies
  • See All Rankings
  • Lists Calendar
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • About Us
  • Press Center
  • Work At Fortune
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.